NICE recommends Lilly's Bydureon, but which GLP-agonist will top UK market?
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued limited draft guidance recommending Lilly's GLP1-agonist Bydureon (exenatide extended-release for injectable suspension) for patients with type 2 diabetes. The drug will now compete against other NICE-recommended GLP-1 agonists, the first-in-class Byetta (Lilly's twice daily exenatide) and Novo Nordisk's Victoza (liraglutide), although it is unclear which one will emerge most successful.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.